Literature DB >> 14734189

Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis.

Vladimir A Karginov1, Tanisha M Robinson, Jenny Riemenschneider, Basil Golding, Michael Kennedy, Joseph Shiloach, Ken Alibek.   

Abstract

Currently there is no effective treatment for inhalational anthrax beyond administration of antibiotics shortly after exposure. There is need for new, safe and effective treatments to supplement traditional antibiotic therapy. Our study was based on the premise that simultaneous inhibition of lethal toxin action with antibodies and blocking of bacterial growth by antibiotics will be beneficial for the treatment of anthrax. In this study, we tested the effects of a combination treatment using purified rabbit or sheep anti-protective antigen (PA) antibodies and the antibiotic ciprofloxacin in a rodent anthrax model. In mice infected with a dose of Bacillus anthracis Sterne strain corresponding to 10 LD(50), antibiotic treatment with ciprofloxacin alone only cured 50% of infected animals. Administration of anti-PA IgG in combination with ciprofloxacin produced 90-100% survival. These data indicate that a combination of antibiotic/immunoglobulin therapy is more effective than antibiotic treatment alone in a rodent anthrax model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734189     DOI: 10.1016/S0928-8244(03)00302-X

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  27 in total

1.  Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors:  Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Authors:  Arnold Louie; Brian D Vanscoy; Henry S Heine; Weiguo Liu; Terry Abshire; Kari Holman; Robert Kulawy; David L Brown; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Histopathology in a murine model of anthrax.

Authors:  Scott Duong; Lucius Chiaraviglio; James E Kirby
Journal:  Int J Exp Pathol       Date:  2006-04       Impact factor: 1.925

5.  In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.

Authors:  Mahtab Moayeri; Tanisha M Robinson; Stephen H Leppla; Vladimir A Karginov
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

6.  A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.

Authors:  Adva Mechaly; Haim Levy; Eyal Epstein; Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Avigdor Shafferman; Arie Ordentlich; Ohad Mazor
Journal:  J Biol Chem       Date:  2012-08-06       Impact factor: 5.157

7.  A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Authors:  Paul Warrener; Reena Varkey; Jessica C Bonnell; Antonio DiGiandomenico; Maria Camara; Kimberly Cook; Li Peng; Jingying Zha; Partha Chowdury; Bret Sellman; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

8.  Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Bacillus anthracis Spores in Suspicious White Powders and Environmental Samples.

Authors:  Jason G Ramage; Kristin W Prentice; Lindsay DePalma; Kodumudi S Venkateswaran; Sruti Chivukula; Carol Chapman; Melissa Bell; Shomik Datta; Ajay Singh; Alex Hoffmaster; Jawad Sarwar; Nishanth Parameswaran; Mrinmayi Joshi; Nagarajan Thirunavkkarasu; Viswanathan Krishnan; Stephen Morse; Julie R Avila; Shashi Sharma; Peter L Estacio; Larry Stanker; David R Hodge; Segaran P Pillai
Journal:  Health Secur       Date:  2016 Sep-Oct

Review 9.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.